NCT02499835View on ClinicalTrials.gov

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 1, 2015

Primary Completion Date

August 9, 2021

Study Completion Date

July 27, 2023

Conditions
Hormone-Resistant Prostate CancerMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Soft TissuesMetastatic Prostate CarcinomaProstate AdenocarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

BIOLOGICAL

pTVG-HP Plasmid DNA Vaccine

Given ID

Trial Locations (1)

53792

University of Wisconsin Carbone Cancer Center, Madison

Sponsors
All Listed Sponsors
collaborator

Prostate Cancer Foundation

OTHER

collaborator

Madison Vaccines Incorporated

INDUSTRY

lead

University of Wisconsin, Madison

OTHER